The Taizhou Medical City Biomedical Pilot Platform, operated by Jiangsu Huatai Vaccine Engineering Technology Research in Taizhou, Jiangsu province, was recently included in the first group of national key cultivation pilot platforms.
Pilot platforms strive to meet the innovative development needs of the manufacturing industry. They gather various industrial resources, promote the commercialization and application of scientific and technological achievements, and provide professional services and systematic solutions.
Taizhou Medical City Biomedical Pilot Platform mainly serves China Medical City, providing one-stop biological product research and development services for enterprises in areas such as technology research and pilot production.
The platform has established industry-university-research cooperation relationships with first tier enterprises and institutions.
Its current research projects include a new adjuvant 9-valent cervical cancer vaccine, a 24 valent pneumococcal conjugate vaccine, and a recombinant herpes zoster vaccine.
So far, the platform has assisted companies in obtaining a total of 18 clinical trial approvals for drugs.